OXBOF (Oxford BioDynamics) Total Assets: $10.93 Mil (As of Sep. 2025)


What is Oxford BioDynamics Total Assets?

Oxford BioDynamics OXBOF -33.33% Total Assets is $10.93 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Oxford BioDynamics's Total Assets for the quarter that ended in Sep. 2025 was $10.93 Mil.

During the past 12 months, Oxford BioDynamics's average Total Assets Growth Rate was -27.90% per year. During the past 3 years, the average Total Assets Growth Rate was -13.50% per year. During the past 5 years, the average Total Assets Growth Rate was 8.60% per year. During the past 10 years, the average Total Assets Growth Rate was 24.60% per year.

During the past 13 years, Oxford BioDynamics's highest 3-Year average Total Assets Growth Rate was 60.60%. The lowest was -13.50%. And the median was 33.45%.

Total Assets is connected with ROA %. Oxford BioDynamics's annualized ROA % for the quarter that ended in Sep. 2025 was -103.87%. Total Assets is also linked to Revenue through Asset Turnover. Oxford BioDynamics's Asset Turnover for the quarter that ended in Sep. 2025 was 0.05.


Oxford BioDynamics  (OTCPK:OXBOF) Total Assets Explanation

Total Assets is connected with ROA %.

Oxford BioDynamics's annualized ROA % for the quarter that ended in Sep. 2025 is

ROA %=Net Income (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=-14.6/( (17.186+10.927)/ 2 )
=-14.6/14.0565
=-103.87 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Oxford BioDynamics's Asset Turnover for the quarter that ended in Sep. 2025 is

Asset Turnover
=Revenue (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=0.686/( (17.186+10.927)/ 2 )
=0.686/14.0565
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Oxford BioDynamics Total Assets Related Terms


Oxford BioDynamics Total Assets Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Total Assets Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.13 12.85 19.96 16.02 10.93

Oxford BioDynamics Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.96 14.06 16.02 17.19 10.93

Oxford BioDynamics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Oxford BioDynamics's Total Assets for the fiscal year that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (A: Sep. 2025 )+Total Liabilities (A: Sep. 2025 )
=1.508+9.419
=10.93

Oxford BioDynamics's Total Assets for the quarter that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (Q: Sep. 2025 )+Total Liabilities (Q: Sep. 2025 )
=1.508+9.419
=10.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $10.93 Mil mean?
Oxford BioDynamics (OXBOF) has a Total Assets of $10.93 Mil as of Sep. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Oxford BioDynamics and its competitors.
Is Oxford BioDynamics' Total Assets too high?
Oxford BioDynamics' current Total Assets is $10.93 Mil.
How does Oxford BioDynamics' Total Assets compare to TMO and DHR?
Oxford BioDynamics' Total Assets of $10.93 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Total Assets is $10.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.00 — trading 96.7% below its estimated fair value. The current Total Assets is $10.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Total Assets is $10.93 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.